Index eyes bargains in biotech

Reuters UK – Bombed-out valuations present an unprecedented buying opportunity in the European biotech sector, according to venture capital firm Index Ventures, which is eyeing both early and late-stage opportunities.

"It’s like being in a candy shop," partner Francesco De Rubertis told Reuters. "I’m very optimistic about the fact that a year from now, or a year and a half from now, the market will be very high."

He sees a major disconnect in current pricing for biotech assets, with Big Pharma companies regularly paying 50 to 100 percent takeover premiums for businesses that have been shunned by risk-averse investors.

Europe is a particularly fertile ground because of its relative immaturity.

Read Complete Article

About the HedgeCo News Team

The Hedge Fund News Team stays on top of breaking news in the Hedge Fund industry on an hourly basis. Signup to HedgeCo.Net to recieve Daily or Weekly news updates from our team.
This entry was posted in Syndicated and tagged , , , , , , . Bookmark the permalink.

Comments are closed.